Brokerages Set Axsome Therapeutics, Inc. (NASDAQ:AXSM) Target Price at $267.60

Posted by Geri Gentry on Sep 10th, 2026

Axsome Therapeutics, Inc. (NASDAQ:AXSM – Get Free Report) has been given an average rating of “Moderate Buy” by the twenty-two analysts that are presently covering the firm, MarketBeat reports. One research analyst has rated the stock with a sell recommendation, two have issued a hold recommendation, seventeen have assigned a buy recommendation and two have issued a strong buy recommendation on the company. The average twelve-month target price among brokerages that have covered the stock in the last year is $267.60.

AXSM has been the subject of a number of research analyst reports. Wells Fargo & Company increased their target price on Axsome Therapeutics from $255.00 to $256.00 and gave the company an “overweight” rating in a report on Tuesday, August 11th. Morgan Stanley lifted their price target on Axsome Therapeutics from $242.00 to $251.00 and gave the stock an “equal weight” rating in a research note on Tuesday, August 11th. Truist Financial upgraded Axsome Therapeutics to a “strong-buy” rating in a research report on Monday, June 15th. Mizuho increased their price objective on Axsome Therapeutics from $306.00 to $316.00 and gave the company an “outperform” rating in a research note on Wednesday, August 12th. Finally, Jefferies Financial Group restated a “buy” rating and issued a $380.00 price objective on shares of Axsome Therapeutics in a report on Thursday, June 11th.

View Our Latest Analysis on AXSM

Insider Transactions at Axsome Therapeutics

In other news, CEO Herriot Tabuteau sold 4,660 shares of the firm’s stock in a transaction dated Thursday, August 6th. The shares were sold at an average price of $213.95, for a total value of $997,007.00. Following the transaction, the chief executive officer directly owned 7,229 shares of the company’s stock, valued at approximately $1,546,644.55. This trade represents a 39.20% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, COO Mark Jacobson sold 10,000 shares of the business’s stock in a transaction dated Thursday, September 3rd. The stock was sold at an average price of $208.65, for a total transaction of $2,086,500.00. Following the transaction, the chief operating officer owned 10,000 shares in the company, valued at $2,086,500. The trade was a 50.00% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 109,330 shares of company stock valued at $24,557,062 over the last quarter. Company insiders own 20.60% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in AXSM. Sequoia Financial Advisors LLC acquired a new stake in shares of Axsome Therapeutics in the second quarter valued at approximately $217,000. Integrated Wealth Concepts LLC purchased a new stake in Axsome Therapeutics in the 2nd quarter valued at $251,000. NewEdge Advisors LLC purchased a new stake in Axsome Therapeutics in the 2nd quarter valued at $277,000. IFP Advisors Inc increased its stake in shares of Axsome Therapeutics by 2.1% in the 2nd quarter. IFP Advisors Inc now owns 62,273 shares of the company’s stock worth $15,243,000 after acquiring an additional 1,279 shares during the last quarter. Finally, Baird Financial Group Inc. purchased a new position in shares of Axsome Therapeutics during the 2nd quarter worth $2,497,000. 81.49% of the stock is currently owned by institutional investors and hedge funds.

Axsome Therapeutics Price Performance

Shares of NASDAQ AXSM opened at $210.63 on Monday. The company has a debt-to-equity ratio of 1.52, a quick ratio of 1.34 and a current ratio of 1.43. The firm has a fifty day moving average of $221.78 and a 200 day moving average of $208.16. The firm has a market cap of $11.03 billion, a PE ratio of -56.17 and a beta of 0.71. Axsome Therapeutics has a one year low of $112.90 and a one year high of $260.19.

Axsome Therapeutics (NASDAQ:AXSM – Get Free Report) last released its earnings results on Monday, August 10th. The company reported ($0.99) EPS for the quarter, missing analysts’ consensus estimates of ($0.89) by ($0.10). The company had revenue of $218.38 million for the quarter, compared to analysts’ expectations of $221.11 million. Axsome Therapeutics had a negative return on equity of 265.55% and a negative net margin of 24.68%. As a group, research analysts predict that Axsome Therapeutics will post -2.8 EPS for the current fiscal year.

About Axsome Therapeutics

(Get Free Report)

Axsome Therapeutics, Inc is a clinical-stage biopharmaceutical company dedicated to developing novel therapies for central nervous system (CNS) disorders. The company focuses on small-molecule drugs designed to address unmet medical needs in areas such as depression, migraine, narcolepsy and fibromyalgia. Axsome employs a precision medicine approach, leveraging pharmacologic innovation to target underlying mechanisms of disease and improve patient outcomes.

Axsome’s pipeline includes several late-stage and approved product candidates.

Analyst Recommendations for Axsome Therapeutics (NASDAQ:AXSM)

Receive News & Ratings for Axsome Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Axsome Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.